article thumbnail

DEA Regs Bulk Up with 2014 Anabolic Steroid Control Law Additions

FDA Law Blog: Biosimilars

Because anabolic steroids are also abused to enhance athletic performance and increase muscle strength, Congress has enacted three laws regulating anabolic steroids: the Anabolic Steroid Control Acts of 1990 and 2004, and the Designer Anabolic Steroid Control Act of 2014 (“DASCA”). DASCA became law, amending the CSA, on December 18, 2014.

article thumbnail

STAT+: GSK is replacing its popular Flovent inhaler with authorized generics, raising cost concerns for asthma patients

STAT

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “ authorized generic ,” essentially the same product sold under a private label. Prasco, a U.S.

Labelling 332
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amgen builds Otezla’s psoriasis label as rival BMS looms large

pharmaphorum

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted rival deucravacitinib, which could make its debut next year. The post Amgen builds Otezla’s psoriasis label as rival BMS looms large appeared first on.

article thumbnail

From GRP to SIUU – the Evolution of FDA Guidance on Off-Label Dissemination of Scientific Information

FDA Law Blog: Biosimilars

Previous iterations of this guidance from 2009 and 2014 (blogged on here and here ) were known as Good Reprint Practices (GRP). The SIUU Guidance, which supersedes the 2014 Draft GRP Guidance, is not substantially different in that regard and contains similar information as to the types of disclosures previously recommended.

article thumbnail

J&J receives full approval from US FDA and European Commission for SIRTURO

Express Pharma

With the FDA’s approval, label restrictions that were included when the medicine was granted accelerated approval in the US in December 2012 are removed. SIRTURO was granted accelerated approval by the FDA in December 2012 and conditional approval by the EMA in March 2014 following positive Phase 2 study data.

article thumbnail

It Finally Happened – FDA’s OPDP Issues First Letter of 2023

Eye on FDA

The numbers plummet in 2014 until the record low last year of only 4 letters. The label for the medicine includes a boxed warning regarding potential issues related to complications for the liver (toxicity) and heart (QT prolongation). The last letter issued came just over a year ago in June, 2022.

article thumbnail

FDA grants swift review to Lynparza in first-line prostate cancer

pharmaphorum

Lynparza was approved in 2020 as a second-line therapy for homologous recombination repair (HRR) gene-mutated mCRPC last year, but extending its label to include non-HRR patients in the frontline setting would dramatically increase the number of patients eligible for treatment. billion in the first half of this year.

Labelling 108